Renaissance Group LLC Acquires Shares of 294,324 Boston Scientific Corporation $BSX

Renaissance Group LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the fourth quarter, HoldingsChannel reports. The firm bought 294,324 shares of the medical equipment provider’s stock, valued at approximately $28,064,000.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after acquiring an additional 1,436,550 shares in the last quarter. Capital World Investors increased its stake in Boston Scientific by 1.9% during the fourth quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares during the last quarter. Norges Bank acquired a new stake in shares of Boston Scientific during the fourth quarter worth $2,199,395,000. Invesco Ltd. raised its holdings in shares of Boston Scientific by 0.7% during the third quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after purchasing an additional 111,826 shares during the period. Finally, Northern Trust Corp lifted its position in shares of Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after buying an additional 128,188 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In other news, Director Edward J. Ludwig bought 3,580 shares of the company’s stock in a transaction that occurred on Wednesday, May 20th. The shares were purchased at an average price of $56.68 per share, with a total value of $202,914.40. Following the completion of the acquisition, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David C. Habiger bought 2,250 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This trade represents a 19.35% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 9,800 shares of company stock valued at $554,012 over the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

BSX stock opened at $48.42 on Thursday. The company has a 50-day simple moving average of $56.99 and a 200 day simple moving average of $75.49. The company has a market capitalization of $71.98 billion, a P/E ratio of 20.26, a PEG ratio of 0.92 and a beta of 0.56. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a fifty-two week low of $47.17 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. Boston Scientific’s revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has authorized a share buyback program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. Needham & Company LLC reaffirmed a “buy” rating and set a $77.00 price objective on shares of Boston Scientific in a research report on Monday, May 18th. Jefferies Financial Group cut their target price on shares of Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Robert W. Baird set a $70.00 target price on Boston Scientific in a research note on Thursday, May 28th. Zacks Research lowered Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.92.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.